← Leaderboards
David A Dichek
J. David Gladstone Institutes
$21,777,395
Attributed
$22,530,996
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$22,530,996 · 8
By mechanism
R01$13,816,720 · 6
T32$8,272,929 · 1
R21$441,347 · 1
Top collaborators
- Francis Kim4 shared
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- John M Taylor$2,619,947
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisCardiovascular SystemPreventMorbidity - Disease RateLaboratoriesBlood VesselsGene TherapyGrowthGene ExpressionTraining ProgramsBaseResearch TrainingAnimal ModelMedicalMyocardial InfarctionResearch StudyInflammationArteriesStrokeOryctolagus CuniculusLesionAdenovirusesGene TransferVascular Diseases
Grant awards (53)
Cardiovascular Research Training Program$328,806
T32 · FY2023 · HL
Atheroprotective Gene Therapy$720,435
R01 · FY2022 · HL · contact PI
Cardiovascular Research Training Program$414,507
T32 · FY2022 · HL
Atheroprotective Gene Therapy$720,435
R01 · FY2021 · HL · contact PI
Cardiovascular Research Training Program$395,247
T32 · FY2021 · HL
Atheroprotective Gene Therapy$720,435
R01 · FY2020 · HL · contact PI
Atheroprotective Gene Therapy$739,701
R01 · FY2019 · HL · contact PI
Cardiovascular Research Training Program$368,643
T32 · FY2019 · HL · contact PI
Cardiovascular Research Training Program$5,119
T32 · FY2017 · HL · contact PI
Cardiovascular Research Training Program$2,528
T32 · FY2017 · HL · contact PI
Atheroprotective Gene Therapy$511,548
R01 · FY2016 · HL · contact PI
Roles of SMC TGF-beta Signaling in Aortic Health and Aneurysm Formation$386,250
R01 · FY2016 · HL · contact PI
Cardiovascular Research Training Program$240,436
T32 · FY2016 · HL · contact PI
Cardiovascular Research Training Program$506,304
T32 · FY2015 · HL · contact PI
Atheroprotective Gene Therapy$503,875
R01 · FY2015 · HL · contact PI
Roles of SMC TGF-beta Signaling in Aortic Health and Aneurysm Formation$380,456
R01 · FY2015 · HL · contact PI
Atheroprotective Gene Therapy$501,319
R01 · FY2014 · HL · contact PI
Roles of SMC TGF-beta Signaling in Aortic Health and Aneurysm Formation$378,525
R01 · FY2014 · HL · contact PI
Cardiovascular Research Training Program$371,389
T32 · FY2014 · HL · contact PI
Cardiovascular Research Training Program$503,232
T32 · FY2013 · HL · contact PI
Atheroprotective Gene Therapy$486,995
R01 · FY2013 · HL · contact PI
Roles of SMC TGF-beta Signaling in Aortic Health and Aneurysm Formation$367,710
R01 · FY2013 · HL · contact PI
A proteomic approach for understanding plaque rupture$189,860
R21 · FY2013 · HL · contact PI
Cardiovascular Research Training Program$510,918
T32 · FY2012 · HL · contact PI
A proteomic approach for understanding plaque rupture$251,487
R21 · FY2012 · HL · contact PI
Cardiovascular Research Training Program$322,867
T32 · FY2011 · HL · contact PI
Cardiovascular Research Training Program$494,122
T32 · FY2010 · HL · contact PI
Engineering Blood Vessels to Resist Atherosclerosis$541,481
R01 · FY2009 · HL · contact PI
Cardiovascular Research Training Program$489,974
T32 · FY2009 · HL · contact PI
Mechanisms of Urokinase-induced Vascular Disease$446,075
R01 · FY2009 · HL · contact PI
Engineering Blood Vessels to Resist Atherosclerosis$518,298
R01 · FY2008 · HL · contact PI
Cardiovascular Research Training Program$485,931
T32 · FY2008 · HL · contact PI
Mechanisms of Urokinase-induced Vascular Disease$426,672
R01 · FY2008 · HL · contact PI
Engineering Blood Vessels to Resist Atherosclerosis$516,299
R01 · FY2007 · HL · contact PI
Cardiovascular Research Training Program$469,135
T32 · FY2007 · HL · contact PI
Mechanisms of Urokinase-induced Vascular Disease$424,994
R01 · FY2007 · HL · contact PI
Cardiovascular Research Training Program$517,632
T32 · FY2006 · HL · contact PI
Engineering Blood Vessels to Resist Atherosclerosis$515,694
R01 · FY2006 · HL · contact PI
Mechanisms of Urokinase-induced Vascular Disease$425,171
R01 · FY2006 · HL · contact PI
Transforming Growth Factor Betal and Arterial Disease$465,782
R01 · FY2005 · HL
Mechanisms of Urokinase-induced Vascular Disease$422,721
R01 · FY2005 · HL
Cardiovascular Research Training Program$234,481
T32 · FY2005 · HL
Cardiovascular Research Training Program$542,477
T32 · FY2004 · HL
Transforming Growth Factor Betal and Arterial Disease$452,215
R01 · FY2004 · HL
Cardiovascular Research Training Program$511,969
T32 · FY2003 · HL
Transforming Growth Factor Betal and Arterial Disease$439,044
R01 · FY2003 · HL
Cardiovascular Research Training Program$557,212
T32 · FY2002 · HL
Transforming Growth Factor Betal and Arterial Disease$426,257
R01 · FY2002 · HL
GENETIC ENGINEERING OF VASCULAR TISSUE$303,200
R01 · FY2002 · HL
Transforming Growth Factor Betal and Arterial Disease$414,933
R01 · FY2001 · HL
GENETIC ENGINEERING OF VASCULAR TISSUE$304,000
R01 · FY2001 · HL
GENETIC ENGINEERING OF VASCULAR TISSUE$244,188
R01 · FY2000 · HL
GENETIC ENGINEERING OF VASCULAR TISSUE$112,012
R01 · FY2000 · HL